Pao W - Search Results

1

Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization.

Redente EF, Dwyer-Nield LD, Merrick DT, Raina K, Agarwal R, Pao W, Rice PL, Shroyer KR, Malkinson AM. Redente EF, et al. Among authors: pao w. Am J Pathol. 2010 Jun;176(6):2972-85. doi: 10.2353/ajpath.2010.090879. Epub 2010 Apr 29. Am J Pathol. 2010. PMID: 20431028 Free PMC article.

2

Serum levels of surfactant protein D are increased in mice with lung tumors.

Zhang F, Pao W, Umphress SM, Jakowlew SB, Meyer AM, Dwyer-Nield LD, Nielsen LD, Takeda K, Gelfand EW, Fisher JH, Zhang L, Malkinson AM, Mason RJ. Zhang F, et al. Among authors: pao w. Cancer Res. 2003 Sep 15;63(18):5889-94. Cancer Res. 2003. PMID: 14522914

3

Serum levels of surfactant protein D are increased in mice with lung tumors.

Zhang F, Pao W, Umphress S, Jakowlew S, Meyer AM, Dwyer-Nield LD, Takeda K, Gelfand EW, Fisher J, Malkinson AM, Mason RJ. Zhang F, et al. Among authors: pao w. Chest. 2004 May;125(5 Suppl):109S. Chest. 2004. PMID: 15136449 No abstract available.

4

BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical models.

Christiani DC, Pao W, DeMartini JC, Linnoila RI, Malkinson AM, Onn A, Politi KA, Sharp M, Wong KK. Christiani DC, et al. Among authors: pao w. J Thorac Oncol. 2006 Nov;1(9 Suppl):S2-7. J Thorac Oncol. 2006. PMID: 17409996 Free article.

5

Genetically informed lung cancer medicine.

Pao W, Iafrate AJ, Su Z. Pao W, et al. J Pathol. 2011 Jan;223(2):230-40. doi: 10.1002/path.2788. Epub 2010 Oct 25. J Pathol. 2011. PMID: 21125677

6

How genetically engineered mouse tumor models provide insights into human cancers.

Politi K, Pao W. Politi K, et al. Among authors: pao w. J Clin Oncol. 2011 Jun 1;29(16):2273-81. doi: 10.1200/JCO.2010.30.8304. Epub 2011 Jan 24. J Clin Oncol. 2011. PMID: 21263096 Free PMC article. Review.

7

Update on epidermal growth factor receptor mutations in non-small cell lung cancer.

Riely GJ, Politi KA, Miller VA, Pao W. Riely GJ, et al. Among authors: pao w. Clin Cancer Res. 2006 Dec 15;12(24):7232-41. doi: 10.1158/1078-0432.CCR-06-0658. Clin Cancer Res. 2006. PMID: 17189394 Review.

8

Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.

Kawabata S, Mercado-Matos JR, Hollander MC, Donahue D, Wilson W 3rd, Regales L, Butaney M, Pao W, Wong KK, Jänne PA, Dennis PA. Kawabata S, et al. Among authors: pao w. Cell Rep. 2014 Jun 26;7(6):1824-32. doi: 10.1016/j.celrep.2014.05.039. Epub 2014 Jun 12. Cell Rep. 2014. PMID: 24931608 Free PMC article.

9

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.

Pirazzoli V, Ayeni D, Meador CB, Sanganahalli BG, Hyder F, de Stanchina E, Goldberg SB, Pao W, Politi K. Pirazzoli V, et al. Among authors: pao w. Clin Cancer Res. 2016 Jan 15;22(2):426-35. doi: 10.1158/1078-0432.CCR-15-0620. Epub 2015 Sep 4. Clin Cancer Res. 2016. PMID: 26341921 Free PMC article.

10

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Pao W, et al. PLoS Med. 2005 Mar;2(3):e73. doi: 10.1371/journal.pmed.0020073. Epub 2005 Feb 22. PLoS Med. 2005. PMID: 15737014 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

244 results

Search Page

Filters